Jürgen Kurt Rockstroh

Jürgen Kurt Rockstroh's AcademicInfluence.com Rankings

Psychology

#3372

World Rank

#3812

Historical Rank

Neuropsychology

#100

World Rank

#103

Historical Rank

psychology Degrees

Jürgen Kurt Rockstroh

Philosophy

#8452

World Rank

#11839

Historical Rank

Logic

#5485

World Rank

#6890

Historical Rank

philosophy Degrees

Download Badge

Psychology
Philosophy

Why Is Jürgen Kurt Rockstroh Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jürgen Kurt Rockstroh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. (2004) (1068)
Raltegravir with optimized background therapy for resistant HIV-1 infection. (2008) (570)
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection (2003) (565)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. (2008) (544)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study (2019) (512)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 (2005) (505)
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. (2005) (402)
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection (2003) (392)
Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution (2005) (379)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial (2012) (334)
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials (2019) (309)
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. (2004) (301)
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. (2009) (296)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. (2015) (288)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. (2012) (270)
Care of patients with hepatitis C and HIV co-infection. (2004) (254)
Beyond viral suppression of HIV – the new quality of life frontier (2016) (227)
HIV-related stigma within communities of gay men: A literature review (2011) (227)
Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV (2013) (221)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2019) (221)
Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK (2013) (219)
Variant of hepatitis B virus with primary resistance to adefovir. (2006) (214)
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. (2010) (200)
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission (2018) (193)
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. (2002) (193)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (2017) (192)
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. (2011) (191)
HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans (2016) (188)
The way forward in HCV treatment — finding the right path (2008) (187)
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study (2015) (185)
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 (2007) (184)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. (2008) (182)
Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. (1997) (180)
Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3+ T Regulatory Cells Correlates with Progressive Disease (2010) (177)
Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany—A Case-Control Study (2011) (177)
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. (2011) (170)
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. (2013) (166)
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations (2018) (160)
HIV and hepatitis C virus co-infection. (2004) (159)
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? (2005) (159)
Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) (2013) (158)
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. (2017) (156)
Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries (2013) (149)
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies (2015) (133)
Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients (1997) (133)
The way forward in HCV treatment — finding the right path (2007) (127)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. (2013) (125)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study (2018) (123)
A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results (2013) (121)
HIV and the heart: the impact of antiretroviral therapy: a global perspective. (2013) (119)
Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing (2006) (119)
Influence of viral hepatitis on HIV infection. (2006) (112)
Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? (2017) (111)
Computational methods for the design of effective therapies against drug resistant HIV strains (2005) (111)
Antiretroviral drug toxicity -- a challenge for the hepatologist? (2002) (110)
Frequency of the HIV-protective CC chemokine receptor 5-Δ32/Δ32 genotype is increased in hepatitis C (2002) (107)
Natural history and management of hepatitis C: does sex play a role? (2014) (105)
Regulation of CC chemokine receptor 5 in Hepatitis G virus infection (2003) (102)
Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients (2004) (99)
HIV-Related Stigma, Isolation, Discrimination, and Serostatus Disclosure (2012) (97)
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. (2012) (92)
Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection (2007) (90)
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (2019) (88)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. (2014) (87)
Compensatory Mutations at the HIV Cleavage Sites P7/P1 and P1/P6-Gag in Therapy-Naive and Therapy-Experienced Patients (2006) (83)
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. (2018) (83)
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. (2014) (82)
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). (2016) (81)
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials (2019) (81)
Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. (2006) (80)
Cardiac Magnetic Resonance Reveals Signs of Subclinical Myocardial Inflammation in Asymptomatic HIV-Infected Patients (2016) (79)
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. (2008) (78)
Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients (2007) (77)
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. (2008) (77)
Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy (2017) (76)
Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. (2009) (73)
Malignant thymoma: current status of classification and multimodality treatment (2003) (73)
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations (2004) (72)
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. (2014) (72)
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women (2013) (71)
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. (2013) (71)
Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption (2010) (70)
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection (2008) (68)
The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. (2009) (68)
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. (2017) (67)
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study (2015) (66)
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. (2013) (66)
Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension. (1995) (65)
Progressive Multifocal Leukencephalopathy in Patients on Highly Active Antiretroviral Therapy: Survival and Risk Factors of Death (2004) (65)
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients (2012) (65)
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment (2004) (64)
Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients (1997) (60)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. (2017) (59)
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (2011) (58)
Treatment of Acute HCV Infection in HIV-Positive Patients: Experience from a Multicentre European Cohort (2010) (58)
Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients (2015) (58)
Trends of prevalence of primary HIV drug resistance in Germany. (2007) (57)
An effective interferon‐gamma‐mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus‐positive patients (2014) (56)
CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. (2007) (55)
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. (2002) (54)
Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. (2014) (54)
HIV Treatment Adherence, Patient Health Literacy, and Health Care Provider–Patient Communication (2012) (53)
The German National Registry of Primary Immunodeficiencies (2012–2017) (2019) (52)
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. (2008) (52)
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. (2006) (52)
Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? (2014) (51)
Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study (2012) (51)
Advances in the treatment of HIV/HCV coinfection in adults (2018) (49)
Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. (2002) (49)
Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. (2009) (48)
Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection (2012) (46)
Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected Patients with High and Low CD4+ T-Cell Counts (2007) (46)
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. (2012) (45)
Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. (2016) (45)
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? (2013) (44)
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update (2019) (44)
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements (2009) (44)
Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression (2009) (43)
The treatment of patients with HIV. (2010) (43)
Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co‐infection: Clinically relevant or a diagnostic problem? (2007) (42)
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals (2013) (42)
Late presentation of chronic viral hepatitis for medical care: a consensus definition (2017) (42)
Late presentation of chronic viral hepatitis for medical care: a consensus definition (2017) (42)
Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus‐positive men who have sex with men in Germany (2010) (42)
GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T-cells (2010) (42)
Infection‐related and ‐unrelated malignancies, HIV and the aging population (2016) (41)
PROSPECTIVE ANALYSIS OF THE VALUE OF 24-HOUR AMBULATORY BLOOD PRESSURE ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION (2000) (41)
Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. (1999) (41)
Orthotopic liver transplantation in human immunodeficiency virus (HIV)‐positive patients: Outcome of 7 patients from the Bonn cohort (2005) (41)
Acute hepatitis C infection in HIV-positive patients (2011) (40)
Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK (2012) (40)
TH1 to TH2 Shift of Cytokines in Peripheral Blood of HIV‐Infected Patients Is Detectable by Reverse Transcriptase Polymerase Chain Reaction but Not by Enzyme‐Linked Immunosorbent Assay Under Nonstimulated Conditions (2000) (40)
Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking (2005) (39)
Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. (2002) (39)
Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort (2011) (39)
CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response? (2004) (39)
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV (2021) (39)
Future of hepatitis C therapy: development of direct-acting antivirals. (2011) (39)
State-of-the-art classification and multimodality treatment of malignant thymoma. (2012) (39)
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals (2000) (39)
Causes of death in HIV-infected patients from the Cologne–Bonn cohort (2014) (38)
Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? (2015) (38)
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. (2010) (37)
Acute hepatitis C in HIV-positive individuals. (2008) (37)
Acute Hepatitis C in Patients with HIV (2012) (36)
Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time (2016) (35)
IS STAGE CONVERSION THE INITIATING EVENT FOR REACTIVATION OF TOXOPLASMA GONDII IN BRAIN TISSUE OF AIDS PATIENTS? (2000) (35)
Initial presenting manifestations in 16,486 patients with Inborn Errors of Immunity include infections and non-infectious manifestations. (2021) (35)
Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. (2012) (35)
Current knowledge and future perspectives on acute hepatitis C infection. (2015) (34)
Liver Fibrosis in HIV Patients Receiving a Modern cART (2015) (34)
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus (2020) (34)
Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection? (2005) (33)
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis (2018) (33)
Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies (2020) (33)
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients (2013) (32)
Report of a European Working Group on Late Presentation with HIV Infection: Recommendations and Regional Variation (2010) (32)
The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDS. (2003) (31)
Stress response pattern in obesity and systemic hypertension. (1992) (30)
Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV–HCV Coinfection and Advanced Liver Disease (2016) (30)
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. (2017) (30)
TH1 to TH2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. (2000) (30)
Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men (2019) (30)
PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension (2014) (30)
Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women (2017) (30)
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective (2014) (29)
A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-α (1996) (29)
Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. (2021) (29)
Optimal therapy of HIV/HCV co‐infected patients with direct acting antivirals (2015) (29)
Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection (2016) (29)
Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. (2014) (29)
Faldaprevir and pegylated interferon &agr;-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV (2015) (28)
Antihypertensive therapy. To stop or not to stop? (1991) (28)
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies (2011) (28)
Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis (2018) (27)
Natural history of liver disease and effect of hepatitis C virus on HIV disease progression (2015) (27)
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort (2007) (26)
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. (2019) (26)
Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. (2019) (26)
HIV and cancer in Germany. (2011) (26)
Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference (2010) (25)
Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. (2005) (25)
Treatment of acute hepatitis C infection in HIV-infected patients (2011) (25)
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV (2017) (25)
Hepatology - A Clinical Textbook, Fifth Edition (2014) (25)
Estimating mixed-effects differential equation models (2014) (24)
Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral Therapy (2009) (24)
HIV‐HCV co‐infection facing HCV protease inhibitor licensing: implications for clinicians (2012) (24)
Hepatitis C Coinfection Enhances Sensitization of CD4+ T-Cells Towards Fas-Induced Apoptosis in Viraemic and Haart-Controlled HIV-1-Positive Patients (2011) (23)
Treatment of acute hepatitis C in HIV infection. (2010) (23)
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S (2016) (23)
Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection (2017) (23)
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy (2003) (23)
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis (2015) (22)
Hepatotoxicity and liver disease in the context of HIV therapy (2007) (22)
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015 (2019) (22)
Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers (2014) (22)
Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection (2015) (22)
Drug safety evaluation of maraviroc for the treatment of HIV infection (2012) (22)
Too many people with viral hepatitis are diagnosed late — with dire consequences (2019) (21)
Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients (2018) (21)
S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges (2011) (20)
Management of hepatitis C/HIV coinfection (2006) (20)
Role of HIV‐1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T‐cell count (1998) (20)
Evidence for extensive genotypic diversity and recombination of GB virus C (GBV‐C) in Germany (2011) (20)
Management of Late-presenting Patients with HIV Infection (2010) (19)
Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART) (2021) (19)
Administration of Indinavir and Low-Dose Ritonavir (800/100 Mg Twice Daily) with Food Reduces Nephrotoxic Peak Plasma Levels of Indinavir (2002) (19)
Selective Pressures of HLA Genotypes and Antiviral Therapy on Human Immunodeficiency Virus Type 1 Sequence Mutation at a Population Level (2007) (19)
Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination (2003) (19)
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals (2018) (19)
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients (2013) (18)
HIV and the liver. (2009) (18)
Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis (2019) (18)
Diagnosis and treatment of acute hepatitis C virus infection. (2012) (18)
Atazanavir Exposure is Effective during Pregnancy Regardless of Tenofovir Use (2015) (17)
The transforming growth factor-β high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C (2008) (17)
Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. (2012) (17)
Nephrogenic diabetes insipidus in a patient taking cidofovir (1997) (17)
Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study. (2005) (17)
Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe (2016) (16)
Clinical perspective of fusion inhibitors for treatment of HIV. (2004) (16)
Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. (1992) (16)
Acute myelogenous leukaemia and myelomonocytic blast crisis following polycythemia vera in HIV positive patients: report of cases and review of the literature. (2000) (16)
HIV care models during the COVID-19 era (2020) (16)
Hepatitis C‐associated autoimmunity in patients coinfected with HIV (2005) (16)
Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study (2011) (16)
Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates. (2005) (16)
Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection (2017) (15)
Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? (2010) (15)
The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection (2010) (15)
Hepatic profile analyses of tipranavir in Phase II and III clinical trials (2009) (15)
Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. (2002) (15)
Safety of lopinavir/ritonavir for the treatment of HIV-infection (2005) (15)
HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial (2019) (15)
Bacteremia Caused by a Novel Helicobacter Species in a 28-Year-Old Man with X-Linked Agammaglobulinemia (2010) (15)
Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study. (1999) (15)
Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference. (2006) (15)
HIV Provider–Patient Communication Regarding Cardiovascular Risk (2014) (15)
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection (2021) (15)
Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study) (2019) (14)
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 (2017) (14)
CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis C (2015) (14)
HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany (2011) (14)
Maraviroc, risks and benefits: a review of the clinical literature. (2008) (14)
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1‐coinfected patients (2015) (13)
Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy (2005) (13)
Introduction to Late Presentation for HIV Treatment in Europe (2010) (13)
HIV resistance testing and detected drug resistance in Europe (2015) (13)
The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. (2007) (13)
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C (2006) (13)
Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. (1997) (13)
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
Current treatment options for hepatitis C patients co-infected with HIV (2016) (13)
HIV provider-patient communication regarding cardiovascular risk: results from the AIDS Treatment for Life International Survey. (2014) (12)
Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison (2015) (12)
Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome (2016) (12)
Hepatitis B (HBV) and Hepatitis C (HCV) in the EuroSIDA Cohort: Prevalence and Impact on Mortality, Aids Progression and Response to HAART. (2004) (12)
Evidence of a large international HCV transmission network in HIV-positive men who have sex with men (MSM) (2009) (12)
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany (2015) (12)
92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN) (2004) (12)
Alterations of the NK cell pool in HIV/HCV co-infection (2017) (12)
Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation (2009) (12)
The treatment of chronic hepatitis C virus infection in HIV co-infection (2009) (12)
Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. (2000) (11)
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations (2017) (11)
Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART) (2017) (11)
Telaprevir-Containing Triple Therapy in Acute HCV Coinfection: The CHAT Study (2017) (11)
Prediction of Imminent Complications in HIV‐1‐Infected Patients by Markers of Lymphocyte Apoptosis (2000) (11)
Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. (2019) (11)
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study (2017) (11)
Latent infection of human bocavirus accompanied by flare of chronic cough, fatigue and episodes of viral replication in an immunocompetent adult patient, Cologne, Germany (2016) (11)
HIV mono-infection is associated with an impaired anti-hepatitis C virus activity of natural killer cells (2015) (11)
Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges (2010) (10)
Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays (2015) (10)
Rapid Determination of the Δ32 Deletion in the Human CC-Chemokine Receptor 5 (CCR5) Gene without DNA Extraction by LightCycler Real-Time Polymerase Chain Reaction (2004) (10)
Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. (1999) (10)
Frequent detection of cell‐associated HIV‐1 RNA in patients with plasma viral load <50 copies/ml (2007) (10)
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. (2000) (10)
CD27(+)CD56Bright natural killer cells may be involved in spontaneous clearance of acute hepatitis C in HIV-positive patients (2014) (10)
Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV. (2016) (10)
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. (2009) (10)
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis (2019) (10)
Moderate endurance training (marathon-training) – effects on immunologic and metabolic parameters in HIV-infected patients: the 42 KM cologne project (2017) (10)
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. (2021) (10)
Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non‐obese HIV‐infected patients (2019) (10)
Geno2pheno is predictive of short-term virological response (2002) (9)
Simeprevir ( TMC 435 ) With Pegylated Interferon / Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1 : A Phase 3 Study (2014) (9)
Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic (2014) (9)
Risk Factors Associated with Older Age in Treatment-Naive HIV-Positive Patients (2012) (9)
Associations between HIV-RNA-based indicators and virological and clinical outcomes (2016) (9)
Efficacy and tolerance of low-dose loop diuretics in hypertension. (1994) (9)
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? (2020) (9)
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study. (2001) (9)
[Malaria in the emergency room. Results of the emergency treatment of 137 patients with symptomatic malaria]. (2005) (9)
Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies (2008) (9)
Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. (2004) (8)
High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study (2020) (8)
Pegylated Interferon-α for the Treatment of Sexually Transmitted Acute Hepatitis C in HIV-Infected Individuals (2006) (8)
Elevated serum activity of N-acetyl-beta-glucosaminidase in essential hypertension: diagnostic value and reversal to normal values after antihypertensive therapy. (1991) (8)
Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial (2017) (8)
Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks. (2002) (8)
The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV (2012) (8)
Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART (2019) (8)
Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
Low-threshold SARS-CoV-2 testing facility for hospital staff: Prevention of COVID-19 outbreaks? (2020) (7)
Maraviroc, risks and benefits: a review of the clinical literature (2008) (7)
Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era. (2020) (7)
Renal and systemic hemodynamics in black and white hypertensive patients. (1997) (7)
Liver histopathology in human immunodeficiency virus–hepatitis C virus co‐infected patients with fatal liver disease (2005) (7)
Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 (2007) (7)
Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of successful withdrawal in a hypertensive community. (1997) (7)
Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy (2014) (7)
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption (2019) (7)
Treatment options of AIDS-related lymphoma (2003) (7)
[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]. (2007) (7)
Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination (2022) (7)
Review of tipranavir in the treatment of drug-resistant HIV (2007) (7)
Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial (2015) (7)
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. (2022) (7)
HCV Reinfection Incidence and Outcomes among HIV Infected MSM in Western Europe (2016) (7)
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients? (2020) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Scale‐up of HIV self‐testing (2018) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results (2017) (7)
Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future (2016) (7)
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART) (2015) (7)
Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study. (2020) (7)
Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals (2017) (7)
HIV-2: A summary of present standard of care and treatment options for HIV-2 infected individuals living in Western Europe. (2020) (6)
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naï ve Patients: 192 Week Results from STARTMRK (2011) (6)
Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS) (2020) (6)
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network (2020) (6)
Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction. (2004) (6)
Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials (2010) (6)
Can HCV be eliminated among HIV-positive men who have sex with men in Berlin? A modeling analysis. (2019) (6)
Regional differences in self-reported HIV care and management in the EuroSIDA study (2014) (6)
microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients (2017) (6)
Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection (2020) (6)
Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study (2018) (6)
Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates (2018) (6)
Clinical management of ageing people living with HIV in Europe: the view of the care providers (2020) (6)
Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible? (2018) (5)
Adherence to enfuvirtide and its impact on treatment efficacy. (2008) (5)
Therapy of hepatitis C in HIV-coinfection. (2004) (5)
Article Commentary: Is There a Need for Liver Disease Monitoring in HIV Patients in Africa? (2011) (5)
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects (2012) (5)
Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin (2010) (5)
New agents for the treatment of hepatitis C in patients co-infected with HIV (2013) (5)
Rapid diagnostic test negative Plasmodium falciparum malaria in a traveller returning from Ethiopia (2021) (5)
Influence of endurance training and marathon running on red cell deformability in HIV patients. (2014) (5)
Differential expansion of T‐cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection (2002) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Treatment of Chronic HCV Genotype 1 Coinfection (2015) (5)
HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? (2012) (4)
The effectiveness of indicator disease-based HIV testing across Europe - results from a prospective multi-centre study (2015) (4)
The ARRIBA Concept: Adequate Resorption of Ribavirin (2015) (4)
Obesity and hypertension. (1994) (4)
Human Immunodeficiency Virus–2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe (2020) (4)
PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION (2014) (4)
Integrase inhibitors: Why do we need a new drug class for HIV therapy? (2009) (4)
Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acute‐On‐Chronic Liver Failure (2021) (4)
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. (2012) (4)
STARTVerso4: faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. (2015) (4)
Hyper-IgD and periodic fever syndrome (HIDS) due to compound heterozygosity for G336S and V377I in a 44-year-old patient with a 27-year history of fever (2016) (4)
Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access (2017) (4)
Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1 , Vacc-4 x : a phase 2 randomised , double-blind , placebo-controlled trial (2014) (4)
Randomised comparison of maintenance therapy with trizivir [TZV] + Efavirenz [EFV] vs TZV in naïve HIV-1 infected subjects: TIME Study (2004) (4)
HCV cure for everyone or which challenges remain? (2015) (4)
Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy? (2014) (4)
week 96 efficacy and safety data: Elvitegravir/cobicistat/ emtricitabine/tenofovir Df (quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir Df in treatment-naïve Hiv-1-infected patients : P139 (2013) (4)
Antiviral Drugs and the Treatment of Hepatitis C (2012) (4)
1172 GENETIC VARIATION IN IL28B RS 12979860 AND RESPONSE TO HCV-SPECIFIC TREATMENT IN HCV/HIV CO-INFECTED PATIENTS (2010) (3)
[Treatment of chronic hepatitis C in HIV coinfection]. (2012) (3)
Increased frequency of the CC-chemokine receptor 5-D32/D32 genotype in hepatitis C (2001) (3)
Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece. (2020) (3)
Pulmonary sarcoidosis shortly after spinal tuberculosis infection: a diagnostic challenge (2014) (3)
Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV (2014) (3)
[Antiretroviral therapy of HIV-infections]. (2000) (3)
Management of hepatitis C in HIV-coinfected patients (2012) (3)
Highlights of the Third International Workshop on HIV and Hepatitis Coinfection (2007) (3)
Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort (2011) (3)
HIV/HCV coinfection, HAART, and liver-related mortality (2004) (3)
Second European Round Table on the Future Management of HIV (2015) (3)
HPV-associated anal lesions in HIV+ patients: long-term results regarding quality of life (2020) (3)
Comparison of early target organ damage between blacks and whites with mild systemic arterial hypertension. (1997) (3)
Dietary salt intake modifies cardiac hypertrophy in essential hypertension (1990) (3)
New aspects in the treatment of AIDS-related lymphoma. (2002) (3)
Clinical outcomes in persons coinfected with HIV and HCV: Impact of HCV treatment (2019) (3)
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord (2015) (3)
Treatment of acute hepatitis C in HIV coinfection: Is this a chance for achieving microelimination? (2019) (3)
Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men. (2020) (3)
CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care—a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999–2013 (2016) (3)
Article Commentary: How Important is HIV Therapy for Preventing Liver Fibrosis Progression in HIV–HCV-Coinfected Individuals? (2012) (3)
Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus (2010) (3)
Hepatitis C virus reinfection-more to come? (2017) (3)
Hot Topics in HIV and Hepatitis Coinfection: Noninvasive Diagnosis of Liver Disease, Liver Transplantation, and New Drugs for Treatment of Hepatitis Coinfection (2009) (2)
HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe (2021) (2)
Supplementary material : Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial (2011) (2)
How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study (2016) (2)
Chemokine Receptor ( CCR ) 1 and CCR 5 Surface Expression on Peripheral Blood T Lymphocytes from Patients with Chronic Hepatitis C Infection (2002) (2)
Acute hepatitis C in HIV-infected individuals – recommendations from the NEAT consensus conference The European AIDS Treatment Network ( NEAT ) Acute Hepatitis C Infection Consensus Panel (2010) (2)
[HIV and hepatitis coinfection]. (2005) (2)
PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a retrospective study. (2011) (2)
Pharmacokinetics of Azidothymidine and its Major Metabolite Glucuronylazidothymidine in Hemophiliacs Coinfected With Human Immunodeficiency Virus and Chronic Hepatitis C (1998) (2)
Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine (2012) (2)
Late diagnosis of HIV: An updated consensus definition (2022) (2)
Living donor liver transplant from an HIV-positive individual to an HIV-negative individual: could this become a new reality? (2018) (2)
Single Nucleotide Polymorphisms Associated With Alimentary Fatty Liver Disease Are Not Genetic Risk Factors For Treatment-associated Hepatic Steatosis in HIV Patients On HAART (2013) (2)
The way forward in HCV treatment — finding the right path (2008) (2)
[HPV-related squamous cell carcinoma of the rectum in an HIV-positive patient--a rare differential diagnosis]. (2012) (2)
DELTA HEPATITIS IN HIV-INFECTED INDIVIDUALS IN EUROPE (2011) (2)
[HIV-infection: modern antiretroviral therapy]. (2004) (2)
HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial. (2010) (2)
Non-invasive markers for monitoring fibrosis regression after HCV-cure: what do they promise? (2020) (2)
Effect of HAART on liver-related mortality in patients with HIV/HCV coinfection (2004) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Managing antiretrovirals in co-infected patients in 2012 (2012) (2)
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study (2017) (2)
[Pre-exposure prophylaxis in HIV--a vision or soon a reality?]. (2009) (2)
Challenges in the treatment of HIV and HCV coinfection (2006) (2)
Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients (2022) (2)
The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences (2021) (2)
When is discontinuation of antihypertensive therapy indicated? (1990) (1)
Antiretrovirale Therapie der HIV‐Infektion (2000) (1)
Stratifying the Risk of NAFLD in Patients with HIV Under Combined Antiretroviral Therapy (2021) (1)
Induction therapy with Trizivir plus Efavirenz: Time study (AZL 30004) results at 24 weeks. (2003) (1)
The Cologne–Bonn cohort: lessons learned (2015) (1)
Managing HCV infection: present and future (2014) (1)
[Opportunistic infections: What's new?] (2018) (1)
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. (2015) (1)
Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry (2021) (1)
Targeting mitochondrial dysfunction can restore antiviral activity of NK cells in HIV/HCV coinfection (2019) (1)
Predictors of serofast state after treatment for early syphilis in HIV‐infected patients (2020) (1)
Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum. (2020) (1)
The German PID-net registry (2017) (1)
[Hepatitis C and HIV coinfection. Current aspects of therapy]. (2002) (1)
Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report (2010) (1)
Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry (2018) (1)
Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study. (2020) (1)
[Recommendations to improve the current situation of HIV testing]. (2010) (1)
781-3 Do Racial Differences Effect the Indices of Target Organ Damage in Arterial Hypertension? (1995) (1)
Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis (2006) (1)
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study (2021) (1)
816 THE TGF-β HIGH PRODUCER GENOTYPE IS ASSOCIATED WITH RESPONSE TO HCV-SPECIFIC THERAPY IN HIV-POSITIVE PATIENTS WITH ACUTE HEPATITIS C (2008) (1)
Current therapy of HBV/HIV coinfection (2010) (1)
Hyaluronic Acid as a Prognostic Marker of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients (2009) (1)
411 HEPATITIS C VIRUS REAPPEARANCE IN HIV-INFECTED PATIENTS WITH SPONTANEOUS HCV-RNA CLEARANCE (2009) (1)
409 The DC-signR tandem-repeat polymorphism in hepatitis C virus infection (2004) (1)
Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4+ T-cell Counts (2006) (1)
Phylogenetic analysis ofacute hepatitis Cvirus genotype4 infections among human immunode¢ciency virus-positivemenwho have sexwith men inGermany (2010) (1)
HepHIV2019 Bucharest Conference: challenges of timely and integrated testing and care. (2019) (1)
SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study) (2021) (1)
Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis (2022) (1)
[Antiretroviral treatment of HIV infected patients]. (2003) (1)
Highlights of the International Congress on Drug Therapy in HIV Infection, 23–26 October 2016, Glasgow, UK (2017) (1)
[Treatment of HPV-associated Anal Lesions in HIV-positive Patients - Comparison of Surgical Treatment and Topical Therapy with Imiquimod]. (2018) (1)
Faldaprevir plus pegyliertes Interferon alpha-2a und Ribavirin (PR) bei Patienten mit HIV und Hepatitis C Genotyp (GT)-1 Koinfektion: End of Treatment Response (ETR) – Ergebnisse der Phase III Studie STARTVerso 4 (2014) (1)
SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness (2022) (1)
Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries (2015) (1)
Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany (2018) (1)
Current and future therapies for chronic HBV-infections (2007) (1)
Reply to Bruno et al.: update to HIV–hepatitis C virus consensus guidelines (2004) (1)
Impact of COVID‐19 on HIV late diagnosis in a specialized German centre (2022) (1)
Implementation of EACS vaccination recommendations among people living with HIV (2022) (1)
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study #_#x2013; 2012 #_#x2013; 2015 (2019) (0)
Clinical management of viral coinfections (2010) (0)
Highly active antiretroviral therapy in HIV and hepatitis C coinfected individuals: friend or foe? (2007) (0)
[The prevention of Pneumocystis carinii pneumonia in HIV infection]. (2008) (0)
LEFT VENTRICULAR CONSEQUENCES OF RENAL TRANSPLANTATION AND CALCIUM-CHANNELBLOCKERS. AUTHORS' REPLY (1997) (0)
Six-week treatment for acute hepatitis C in people with HIV (0)
[Abdominal emergencies in patients with AIDS]. (1994) (0)
[Advances in management of HIV infections]. (2012) (0)
Increased risk of antiretroviral drug discontinuation among patients with high hyaluronic acid, a marker of liver firbosis (2013) (0)
Author ' s response to reviews Title : Simeprevir with pegylated interferon alfa 2 a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV : a historical comparison (2015) (0)
Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection (2022) (0)
PROGRESSION OF LlVER FIBROSIS IN HIV / HCV GENOTYPE 1 C OIN FECTED PATIENTS IS RELATED TO THE T ALLELE OF THE Rs 1297 9860 POLYMORPHISM OF THE IL 28 B G ENE (2012) (0)
Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression (2021) (0)
Highlights of the 3rd International Workshop on HIV and Hepatitis Coinfection (2007) (0)
Outcome after Orthotopic Liver Transplantation in 33 Human Immunodeficiency Virus (HIV)-Positive Patients in Germany: Recurrence of Chronic Hepatitis-C Infection after Transplantation: 2103 (2012) (0)
[Epidemiology and transmission of HIV infection]. (1999) (0)
CCR5 ANTAGONISTS: COMPARISONOFEFFICACY, SIDEEFFECTS, PHARMACOKINETICSANDINTERACTIONS- REVIEWOFTHELITERATURE (2007) (0)
331 CO-STIMULATION VIA CD27 MIGHT IMPORTANTLY CONTRIBUTE TO ANTI-HCV ACTIVITY OF NK CELLS (2013) (0)
Outcome of men with HIV-associated germ cell cancer: Results from an international collaborative study. (2020) (0)
HIV and hepatitis C coinfection. (2011) (0)
624 THE CTLA4 +49 A>G POLYMORPHISM AFFECTS RESPONSE TO HEPATITIS C VIRUS-SPECIFIC THERAPY IN HIV+ PATIENTS WITH ACUTE HEPATITIS C (2009) (0)
Genetic polymorphisms in fatty liver disease in HIV positive patients receiving combined antiretroviral therapy (cART) (2016) (0)
Iconographies supplémentaires de l'article : Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial (2011) (0)
Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection (2022) (0)
GBV-C co-infection in HIV patients downregulates CCR5 and CXCR4 surface expression on CD4 cells (2007) (0)
New drugs for HIV therapy. (2005) (0)
P559 CONTINENTAL DIFFERENCES AMONG HIV-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA: EUROPE VS. NORTH AMERICA (2014) (0)
P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT) (2006) (0)
HCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals (2016) (0)
25 years on, HIV is still on the rise in Europe (2017) (0)
Late HIV diagnosis: Where we stand and the way forward (2022) (0)
634 The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection (2003) (0)
P0700 : Immunological rather than virological response to haart is associated with improved anti-HCV NK cell activity in HIV patients (2015) (0)
HCV healing also in HIV infected patients (2017) (0)
Impact of therapeutic, anthropometric and genetic factors on glucose metabolism in HIV‐patients – a reason for glycemic control? (2006) (0)
Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges? (2009) (0)
Can highly active antiretroviral therapy slow down the progression of hepatitis C disease in patients with HIV coinfection (2007) (0)
[HIV-associated cholangiopathy]. (1994) (0)
[Splenic infarct in a patient with HIV infection]. (2005) (0)
SAT-319-Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients (2019) (0)
1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials (2018) (0)
Trastuzumab resistance: Bringing tailored therapy to the clinic (2008) (0)
Host Gene Polymorphisms and Disease/Treatment Outcomes in HIV and Viral Coinfections (2012) (0)
359 HLA FOOTPRINTS IN HIV/HCV CO-INFECTED PATIENTS (2013) (0)
Epidemiologie und Transmission der HIV-Infektion (2007) (0)
598 The IL6 high producer (HP) genotype (IL6 +174G/G, and +174G/C) is associated with treatment-induced recovery from acute hepatitis C infection in HIV-infected patients (2006) (0)
881 ALTERED EXPRESSION OF DEATH RECEPTORS AND THEIR LIGANDS AS A MECHANISM FOR ENHANCED CD4+ T CELL APOPTOSIS IN HIV/HCV CO-INFECTION (2009) (0)
Epidemiological and virological characteristics of chronic HBV infection in HIV-positive patients in Europe from 1994-2006 (2009) (0)
Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study). (2022) (0)
Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North Amer- (2011) (0)
The Spectrum of Malignancies in the Era of HAART (2009) (0)
The use of intrahepatic portosystemic shunt in HIV positive patients: A retrospective multicentric study. (2019) (0)
Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial. (2022) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
[Current therapeutic protocols and efficacy of new antiretroviral drugs for the treatment of HIV infection taking into consideration gender-specific profile of side effects]. (1999) (0)
[Long-term results of a surgery-only treatment (the Veau-Axhausen-Mirault method) in patients with clefts of the lip, jaw, palate and velum at a surgical clinic]. (1982) (0)
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct‐acting antivirals—Results from the EuroSIDA study (2022) (0)
Massive Paraesophageal Varices in the Absence of Liver Cirrhosis. (2017) (0)
HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges? (2019) (0)
Why we need to re‐define long‐term success for people living with HIV (2023) (0)
Circulating levels of Pro-C3 reflect liver fibrosis and function in HIV positive patients receiving cART (2016) (0)
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina Reekie, (2018) (0)
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study (2021) (0)
P1284 : Establishment of an interdisciplinary online expert-forum (INXFO) specialized in HIV and hepatitis in Germany – up-date 2014 (2015) (0)
[HIV infection : Test and treatment]. (2016) (0)
Hepatitis C (HCV) microelimination in HIV-coinfected men who have sex with men (MSM): A low hanging fruit? (2020) (0)
Uptake of Tenofovir-based Combination Antiretroviral Therapy (cART) among HIV/HBV Co-infected Patients in the EuroSIDA Study (2015) (0)
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination (2022) (0)
P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS (2014) (0)
P3NP-levels in patients with HIV/HCV-co-infection reflects fibrosis stage and hepatic venous pressure gradient (2014) (0)
Mitochondrial dysfunction contributes to impaired cytokine production of CD56 bright NK cells from HIV(+) individuals under effective antiviral therapy. (2022) (0)
Medical-professional rehabilitation after cancer – 2-years experience and evaluation of a multimodal rehabilitation concept (2018) (0)
733 NEOEPITOPES DERIVED FROM EXTRACELLULAR MATRIX DEGRADATION REFLECT LIVER FUNCTION, FIBROSIS AND HVPG IN HIV-PATIENTS (2013) (0)
861 THE IMPACT OF IL28B rs12979860 SNP AND ADVANCED LIVER FIBROSIS ON RESPONSE-GUIDED THERAPY IN HIV/HCV COINFECTED PATIENTS OF PARTICULAR CLINICAL INTEREST (2013) (0)
H41 Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation (1997) (0)
Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA) (2019) (0)
O35 PREDICTING SURVIVAL OF HIV-INFECTED PATIENTS WITH LIVER CANCER – THE SHILCA SCORE AND STAGING MODEL (2014) (0)
O141: Managing HIV‐HCV co‐infection (2013) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials (2014) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Managing antiretrovirals in co-infected patients in 2012 (2012) (0)
Human immunodeficiency virus infection does not alter T cell immune response to hepatitis C (1998) (0)
Practice Point 31 – How to Manage Hepatitis B Virus in the HIV Coinfected Patient (2017) (0)
Current knowledge and future perspectives on acute hepatitis C 1 (0)
[HIV infection: a chronic disease with new challenges]. (2011) (0)
[What should we pay attention to in combination treatment of HIV infected patients? Interaction problems of protease inhibitors]. (2001) (0)
Der Tandem-Repeat Polymorphism des DC-SIGNR Gens in der Hepatitis C Virus Infektion (2004) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Advances in Antivirals Drugs Strategies (2016) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Efficacy and safety of IFN-free DAA therapy in HIV/HCV co-infected patients: Results from a pan-European study (2018) (0)
Hepatitis C reinfection with protease inhibitor‐resistant hepatitis C virus in an HIV‐coinfected MSM (2020) (0)
HIV-associated microbial translocation may affect cytokine production of CD56bright NK cells via stimulation of monocytes. (2022) (0)
Long‐term success for people living with HIV: A framework to guide practice (2023) (0)
P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL (2014) (0)
HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial (2019) (0)
Orthotopic Liver Transplantation in Human Immunodeficiency Virus (HIV)-Positive Patients in Germany (2011) (0)
1269. Cohort Profile: The Translational Platform HIV (TP-HIV), a Multicenter Cohort Project in Germany (2019) (0)
P.099 Primary resistance of a novel hepatitis B virus variant to adefovir (2006) (0)
External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. (2023) (0)
Correction to: Clinical management of ageing people living with HIV in Europe: the view of the care providers (2020) (0)
Reply to Fierer et al (2012) (0)
[HAART-update for the general practitioner]. (2011) (0)
Announcements and Call for Abstracts (2009) (0)
Short communication Pegylated interferon-α for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals (2006) (0)
782 IMPAIRED CD4+ T CELL-MEDIATED STIMULATION OF NK CELL ANTI-FIBROTIC ACTIVITY MAY CONTRIBUTE TO ACCELERATED PROGRESSION TOWARDS HCV-ASSOCIATED LIVER FIBROSIS IN HIV/HCV CO-INFECTED PATIENTS (2012) (0)
Current Recommendation for First Line Therapy of Uncomplicated Hypertension (1990) (0)
Renal and systemic hemodynamics in black versus white hypertensives. (1996) (0)
Report on Experience in the Treatment of Hepatitis C in HIV-Coinfected Hemophiliacs (2001) (0)
Improved Vascular, Immunological And Oxidative Stress Parameters In Hiv-positive Men Towards Endurance Training: 1529 (2011) (0)
Su1055 Impact of Baseline Variables on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With HIV/HCV Genotype-1 Coinfection in a Phase III Trial (2014) (0)
SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT (2014) (0)
Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV–HCV Coinfection (2014) (0)
[Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice]. (2004) (0)
S2083 Correlation of TRANSIENT ELASTOGRAPHY with APRI and Fib-4 in a Cohort of Patients with Congenital Bleeding Disorders and HCV Infection or HIV/HCV Co-Infection (2009) (0)
Geno2pheno and the Arevir database: tools for determination of clinically relevant cut-offs and prediction of viral load change from HIV-1 genotype. (2003) (0)
High Efficacy of Grazoprevir/Elbasvir Among HCV GT1, GT4, Or GT6 Infected Patients with HIV Co-Infection (2015) (0)
Safety and eﬃ cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial (2014) (0)
COMPARISONOFINDINAVIR+RITONAVIR600+100 mgVS. 400+100 mg BID COMBINATIONSINHIV1-INFECTEDPATIENTSGUIDEDBY THERAPEUTICDRUGMONITORING (2007) (0)
Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV (2023) (0)
SP18-3 Treatment of HIV/HCV co-infection in the DAA era (2013) (0)
A call to action to reclaim focus on testing and early treatment for HIV, viral hepatitis, sexually transmitted infections and tuberculosis (2022) (0)
Rapid diagnostic test negative Plasmodium falciparum malaria in a traveller returning from Ethiopia (2021) (0)
The RANTES (-403 G→A) promoter polymorphism does not affect HCV or HIV/HCV co-infection but is increased in HIV infection (2003) (0)
Patient Outcomes after Discontinuation of Antihypertensive Therapy (1991) (0)
A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB (2020) (0)
(Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States (2019) (0)
Differential immunodominance hierarchy of CD 8 + T-cell responses in HLA-B * 27 (2018) (0)
[HIV and sports: good or evil?]. (2016) (0)
Maraviroc,risksandbenefits: areviewoftheclinicalliterature (2008) (0)
People living with HIV, HCV and HIV/HCV coinfection in intensive care in a German tertiary referral center 2014-2019. (2023) (0)
[The therapy of viral hepatitis in HIV-infected patients]. (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jürgen Kurt Rockstroh?

Jürgen Kurt Rockstroh is affiliated with the following schools:

Jürgen Kurt Rockstroh's Academic­Influence.com Rankings

Why Is Jürgen Kurt Rockstroh Influential?

Jürgen Kurt Rockstroh's Published Works

Published Works

What Schools Are Affiliated With Jürgen Kurt Rockstroh?

Jürgen Kurt Rockstroh's AcademicInfluence.com Rankings